Rapid Diagnostics Market (2025-2032)
The Rapid Diagnostics Market was valued at $14.57 billion in 2024. This market is expected to reach $24.28 billion by 2032 from an estimated $15.47 billion in 2025, at a CAGR of 6.6% during the forecast period from 2025 to 2032. Rapid Diagnostics Market Size & Forecast RDT kits are extensively utilized
- Published
- Jun 2025
- Pages
- 250
- Format
- PDF + Excel
- Report ID
- MRHC - 104553
- Base year
- 2024
- 2024 · BASELINE
- $14.57B
- 2035
- $29.31B
- CAGR 2025–2035
- 6.6%
2024 baseline · 2025–2035 forecast at 6.6% CAGR · hover a bar for the value
Key highlights
The Kits Segment to Account for a Large Share of the Rapid Diagnostics Market in 2024
The Immunoassay Segment to Account for a Large Share of the Rapid Diagnostics Market in 2024
The Infectious Disease Segment to Account for a Large Share of the Rapid Diagnostics Market in 2024
The Blood Segment to Account for the Largest Share of the Rapid Diagnostics Market in 2024
The Hospitals & Clinics Segment to Account for the largest share of the Rapid Diagnostics Market in 2024
Report summary
| Particulars | Details |
|---|---|
| No of Pages | 250 |
| Format | |
| Forecast Period | 2025-2035 |
| Base Year | 2024 |
| CAGR | 6.6% |
| Market Size (Value) | $24.28 Billion by 2032 |
| Segments Covered | By Product · Kits · OTC Kits · Professional Kits · Test Readers/Analyzers · By Platform · Immunoassays · Lateral Flow Assays · Serological Assays · Other Immunoassays · (Note: Other Immunoassays include flow-through immunoassays and agglutination assays) · Molecular Detection · RT-PCR · Isothermal Nucleic Acid Amplification Technology (INAAT) · Other Rapid Diagnostic Platforms · (Note 1: Other Immunoassays include flow-through immunoassays and agglutination assays) · (Note 2: Other rapid diagnostic platforms mainly include coagulation tests, glucose monitoring systems, dipsticks, and other rapid diagnostic platforms) · By Application · Blood Glucose Testing · Cardiac Metabolism Testing · Infectious Diseases Testing · Influenza Testing · COVID-19 testing · HIV Testing · Hepatitis Testing · Hepatitis B · Hepatitis C · Sexually Transmitted Diseases (STD) Testing · Healthcare Associated Infection (HAI) Testing · Respiratory Disease Testing · Tropical Disease Testing · Other Infectious Disease Testing · (Note: Other infectious disease testing includes meningitis, norovirus [stomach flu], hand, foot, and mouth disease [HFMD], and pertussis) · Coagulation Testing · Pregnancy And Fertility Testing · Cardiac Metabolism Testing · Hematology Testing · Tumor/Cancer Markers Testing · Urinalysis · Cholesterol Testing · Other Tests · (Note: Other tests include drugs of abuse, fecal occult, and coagulation tests) · by Sample Type · Blood · Saliva, Nasal and Oropharyngeal · Urine · Other Sample Types · (Note: Other Sample Types include ambulatory care centers, nursing homes, and public places (airports, hotels, and workplaces) · End User · Hospitals & Clinics · Diagnostic Laboratories · Home Care/Self Testing · Other End Users · (Note: Other End Users include ambulatory care centers, nursing homes, and public places (airports, hotels, and workplaces) |
| Countries Covered | North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, Switzerland, Sweden, Netherlands, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of APAC), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa (Saudi Arabia, South Africa, and Rest of Middle East & Africa) |
| Key Companies | Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), ACON Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), BioMérieux S.A. (France), Alfa Scientific Designs, Inc. (U.S.), BTNX Inc. (Canada), Meridian Bioscience, Inc. (U.S.), and Trinity Biotech plc (Ireland) |
Report overview
Segments covered: product. Regions: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
RDT kits are extensively utilized in hospitals and clinical laboratories for the qualitative and quantitative detection of specific antigens, antibodies, and genetic material or proteins related to particular health conditions or diseases. These kits help uncover the underlying mechanisms of disease and empower doctors and healthcare professionals to make critical medical decisions.
The rapid growth of the rapid diagnostics market is driven by several key factors, including the increasing demand for point-of-care (POC) diagnostics, the rising prevalence of chronic diseases alongside an aging population, the need for swift decision-making in emergency departments, and ongoing technological innovations.
Report infographic
.webp)
Market dynamics
5 factors across 3 forcesRising Prevalence of Infectious Diseases
The exponential growth of the human population has resulted in the expansion of human settlements into new geographical areas, increasing the likelihood of contact with animals that may serve as potential hosts for infectious disease agents. This phenomenon has contributed to the emergence of various infectious diseases throughout history. Additionally, there is a rising prevalence of infectious diseases on a global scale. For example, a July 2022 article in the United Nations’ Africa Renewal digital magazine highlighted that the risk of outbreaks caused by zoonotic pathogens, such as the Ebola and monkeypox viruses, is increasing. According to the WHO, there has been a 63% rise in zoonotic disease outbreaks in Africa from 2012 to 2022 compared to the period from 2001 to 2011.
- In September 2023, the Ministry of Health and Family Welfare of India reported six confirmed cases of the Nipah virus in the state of Kerala. As of September 27, 2024, 1,288 contact cases related to the Nipah virus have been reported.
- The global epidemiological burden of sepsis has risen significantly in recent years. According to the WHO, sepsis is estimated to affect over 30 million people worldwide, resulting in approximately 6 million deaths annually.
- In 2021, approximately 38.4 million people were living with HIV, including 1.7 million children. Of this total, 20.6 million (53%) resided in eastern and southern Africa, 5 million (13%) in western and central Africa, 6 million (15%) in Asia and the Pacific, and 2.3 million (5%) in Western and Central Europe and North America.
Rapid diagnostic tests enable the early detection of infectious diseases, which is valuable for controlling their spread. The rising prevalence and outbreaks of infectious diseases are expected to drive the market's growth.
Increasing Need for Rapid Decision-making
Emergency departments in hospitals play a vital role in delivering both inpatient and outpatient services, essential for preventing death or serious health impairment. However, overcrowding in these departments is a well-documented challenge, driven by factors such as the increasing geriatric population and referrals from primary care. To address this issue, rapid diagnostics are being increasingly adopted in emergency departments to improve clinical decision-making related to patient diagnosis, treatment, monitoring, and prognosis. This approach also aims to optimize resource utilization and alleviate overcrowding. The rising number of patient admissions in emergency departments globally further fuels the demand for rapid diagnostic kits.
Table of contents
13 chapters · 161 sections · 250 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2035) |
|---|---|---|
| By Product | Kits | — |
| By Platform | Immunoassay | Molecular detection tests |
| By Application | Infectious disease | Tumor/cancer markers testing |
| By Sample Type | Blood | Blood |
| By End User | Hospitals & Clinics | Home care/self-testing |
By Product
- The Kits Segment to Account for a Large Share of the Rapid Diagnostics Market in 2024
- The kits segment is expected to account for the largest share of 67.6% of the rapid diagnostics market.
- The significant share of this segment can be attributed to the increasing adoption and frequent use of kits.
- Additionally, the expanding portfolio of disease-specific rapid kits for the early diagnosis of chronic and infectious diseases, along with ongoing technological advancements, further supports the segment's substantial market share.
- Moreover, this segment is expected to register the highest CAGR of 7.2% during the forecast period.
By Platform
- The Immunoassay Segment to Account for a Large Share of the Rapid Diagnostics Market in 2024
- The immunoassay segment is expected to account for the largest share of 54.2% of the rapid diagnostics market.
- The substantial share of this segment can be attributed to the high prevalence of infectious and chronic diseases, the lower costs of rapid immunoassay tests compared to traditional laboratory-based tests, ongoing technological innovations, and the increasing demand for lateral flow assay kits suitable for home use.
- However, the molecular detection tests segment is expected to register the highest CAGR of 6.2% during the forecast period.
- The factors driving the segment growth are the high sensitivity and accuracy of these tests, the growing need for advanced diagnostic techniques, and the widening applications of molecular detection tests in various fields.
By Application
- The infectious disease segment is expected to account for the largest share of the rapid diagnostics market.
- The large share of this segment is mainly attributed to the rising prevalence of infectious diseases, high awareness, and major efforts regarding early diagnosis, monitoring, and surveillance of infectious diseases after the COVID-19 pandemic.
- However, the tumor/cancer markers testing segment is expected to register the highest CAGR during the forecast period.
- The factors attributed to this segment’s growth are the rising prevalence of cancer worldwide, growing investments and funding for cancer biomarker research, and advancements in cancer diagnostic technologies.
By Sample Type
- The Blood Segment to Account for the Largest Share of the Rapid Diagnostics Market in 2024
- The blood segment is expected to account for the largest share of the market.
- The large share of this segment is attributed to the high availability of rapid tests requiring blood as the sample, the high tendency of the blood samples to retain the genetic material intact without altering its properties compared to other samples, and easy extraction and storage options for blood samples.
- Moreover, the blood segment is expected to register the highest CAGR during the forecast period due to players' growing focus on launching rapid tests that require blood samples.
By End User
- The hospitals & clinics segment is estimated to account for the largest share of the rapid diagnostics market.
- The large share of this segment is mainly attributed to the increasing number of patient visits to hospitals for various healthcare services, such as diagnosis, treatments, and surgeries with well-equipped operating & diagnostic rooms, the presence of highly skilled healthcare professionals, the ease of accessibility, and better health coverage for hospital-based healthcare services from various private and group insurance plans.
- However, the home care/self-testing segment is expected to register the highest CAGR during the forecast period.
- The rising incidence of chronic diseases necessitating ongoing care and regular monitoring, coupled with the expanding utilization of home healthcare services and the enhanced availability of accessible and advanced point-of-care diagnostic products, are key drivers fueling the demand for rapid diagnostics in home environments.
Geographic analysis
North America
Largest shareIn 2024, North America is expected to account for the largest share of 41% of the rapid diagnostics market. The large share of North America is attributed to the region’s highly developed diagnostic infrastructure, the high number of laboratory tests performed annually, the rising prevalence of chronic diseases coupled with growth in the aging population, the rising number of inpatient admissions, increasing awareness, and the growing adoption of self-testing kits among the general population.
Asia-Pacific
Fastest growthHowever, Asia-Pacific is expected to be the fastest-growing regional market, registering a CAGR of 10.1% during the forecast period. The aging population, the rising prevalence of infectious and chronic diseases, and various government initiatives to promote health awareness drive the rapid diagnostics market in Asia-Pacific.
Competitive landscape
- February 2024
Bio-Rad Laboratories Inc. (U.S.) launched the Vericheck ddPCR Replication Competent Lentivirus Kit and the Vericheck ddPCR Replication Competent AAV Kit. These provide rapid results for absolute quantification of replication-competent lentivirus (RCL) and replication-competent adeno-associated virus.
- March 2023
Abbott Laboratories (U.S.) received approval from the U.S. FDA for the company’s new traumatic brain injury (TBI) blood test.
- February 2023
Beckton, Dickinson, and Company (U.S.) received emergency use approval from the U.S. FDA for its new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B, and Respiratory Syncytial Virus (RSV).
- Becton
- Dickinson and Company (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. · Switzerland
- ACON Laboratories, Inc. (U.S.)
- Creative Diagnostics (U.S.)
- Danaher Corporation (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- BioMérieux S.A. · France
- Alfa Scientific Designs, Inc. (U.S.)
- BTNX Inc. · Canada
- Meridian Bioscience, Inc. (U.S.)
- Trinity Biotech plc · Ireland
Frequently asked questions
The rapid diagnostics market covers the market sizes & forecasts for the various rapid diagnostic kits used for blood glucose testing, cardiac metabolism testing, infectious diseases testing, coagulation testing, pregnancy & fertility testing, fecal occult testing, hematology testing, tumor/cancer markers testing, drugs of abuse testing, urinalysis, and cholesterol testing. The rapid diagnostics market studied in this report involves the value analysis of various segments and subsegments of rapid diagnostic kit producers at the regional and country levels.
Cite this report
Meticulous Research. (2025). Rapid Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 104553). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/rapid-diagnostics-market-5240